

FOR IMMEDIATE RELEASE:

**PROFECTUS BIOSCIENCES TO PRESENT AT
UPCOMING INVESTOR MEETINGS**

Baltimore, MD – March 30, 2009 – Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for chronic viral infections announced today that Shawn P. O'Brien, President and Chief Executive Officer, will present a corporate overview at two leading investor conferences; *BIO National Venture Conference* and the *11th Annual C21 BioVentures*.

Mr. O'Brien will be available for one-on-one meetings with potential investors during both conferences:

What: *BIO National Venture Conference*

When: March 31-April 1, 2009

Where: Boston, MA at the Sheraton Boston Hotel

Presentation: Tuesday, March 31, 2009 from 3:00-3:15 p.m. in the Berkeley room

For more information, please visit <http://bnvc.bio.org/opencms/BioVenture/2009/>

What: The 11th Annual C21 BioVentures

When: April 7-9, 2009

Where: Napa, CA at the Meritage Resort

Presentation: Thursday, April 9 from 2:00-2:15 p.m. in Salon IV

For more information, please visit <http://www.techvision.com/c21/>

About Profectus BioSciences Inc.

Profectus Biosciences, is a research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Company's first clinical vaccine candidate for human immunodeficiency virus (HIV) is planned to be tested in clinical trials in 2009. It is expected that data generated from the series of proof of concept trials will be useful in the clinical development of vaccine candidates for hepatitis C virus (HCV). The Profectus proprietary vaccine design approach combines its rVSV and pDNA platforms via a unique prime boost strategy to advance vaccine research. Profectus broad pipeline will address (HIV), (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV).

Profectus has received over \$36 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime boost vaccines and its anti-inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit:

<http://www.profectusbiosciences.com>.

#

Contact:

Lisa Rivero

LaVoie Group

978-745-4200 x106

lrivero@lavoiegroup.com

<http://www.lavoiegroup.com>